Ginkgo Bioworks Holdings Inc (NYSE: DNA)’s stock price has increased by 14.31 compared to its previous closing price of 6.23. However, the company has seen a 21.11% increase in its stock price over the last five trading sessions. accesswire.com reported 2024-09-17 that – Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing – STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week: 3rd Annual mRNA Process Development & Manufacturing Summit – members of Applied DNA’s Biotherapeutics Sales and Business Development teams (collectively ‘LineaRx,’ a majority-owned Applied DNA company) will attend the 3rd Annual mRNA Process Development & Manufacturing Summit taking place September 17-19, 2024. LineaRx will present its Linea™ IVT platform – a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) – as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
Is It Worth Investing in Ginkgo Bioworks Holdings Inc (NYSE: DNA) Right Now?
Moreover, the 36-month beta value for DNA is 1.07. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DNA is 35.44M and currently, short sellers hold a 20.17% of that float. On September 17, 2024, DNA’s average trading volume was 1.65M shares.
DNA’s Market Performance
DNA’s stock has seen a 21.11% increase for the week, with a -19.62% drop in the past month and a -58.48% fall in the past quarter. The volatility ratio for the week is 8.36%, and the volatility levels for the past 30 days are at 10.93% for Ginkgo Bioworks Holdings Inc The simple moving average for the past 20 days is 2.08% for DNA’s stock, with a -79.51% simple moving average for the past 200 days.
Analysts’ Opinion of DNA
Raymond James gave a rating of “Mkt Perform” to DNA, setting the target price at $2.50 in the report published on November 14th of the previous year.
DNA Trading at -29.91% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.40% of loss for the given period.
Volatility was left at 10.93%, however, over the last 30 days, the volatility rate increased by 8.36%, as shares sank -24.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.16% lower at present.
During the last 5 trading sessions, DNA rose by +20.07%, which changed the moving average for the period of 200-days by -87.30% in comparison to the 20-day moving average, which settled at $6.86. In addition, Ginkgo Bioworks Holdings Inc saw -89.47% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Che Austin, who proposed sale 99 shares at the price of $6.37 back on Sep 17 ’24. After this action, Che Austin now owns shares of Ginkgo Bioworks Holdings Inc, valued at $631 using the latest closing price.
Coen Steven P. sale 316 shares at $6.17 during a trade that took place back on Sep 12 ’24, which means that Coen Steven P. is holding 5,609 shares at $1,950 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -4.07 for the present operating margin
- 0.59 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -4.87. The total capital return value is set at -0.51. Equity return is now at value -76.83, with -45.83 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at -0.65. The debt to equity ratio resting at 0.54. The interest coverage ratio of the stock is -8065.74.
Currently, EBITDA for the company is -600.68 million with net debt to EBITDA at 0.61. When we switch over and look at the enterprise to sales, we see a ratio of 0.66. The receivables turnover for the company is 9.76for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.71.
Conclusion
To wrap up, the performance of Ginkgo Bioworks Holdings Inc (DNA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
